CVA
MCID: CRB039
MIFTS: 63

Cerebrovascular Disease (CVA) malady

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An artery disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to lupus erythematosus and myocardial infarction, and has symptoms including headache, transient ischemic attacks, stereotypic symptoms and angina pectoris. An important gene associated with Cerebrovascular Disease is NOTCH3 (Notch 3), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Heparin and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
id Related Disease Score Top Affiliating Genes
1 lupus erythematosus 30.1 ACE CRP PLAT SELP
2 myocardial infarction 29.0 ACE ADM AGTR1 APOA1 APOB APOE
3 basal ganglia cerebrovascular disease 11.9
4 carasil syndrome 11.4
5 vascular dementia 11.1
6 peripheral artery disease 11.1
7 fabry disease 11.0
8 cadasil 11.0
9 sneddon syndrome 10.9
10 peripheral arterial occlusive disease 1 10.7
11 multisystemic smooth muscle dysfunction syndrome 10.7
12 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 10.7
13 cadasil 2 10.7
14 moyamoya disease 10.5
15 lupus erythematosus panniculitis 10.4 ACE APOE
16 iron metabolism disease 10.4 ACE APOE CRP
17 photosensitive epilepsy 10.4 COL4A1 F2 MTHFR
18 schistosomiasis 10.4 APOE MTHFR NOTCH3
19 bullous skin disease 10.4 ACE F2 MTHFR
20 acute infection of pinna 10.4 CRP F2
21 hypotrichosis simplex 10.4 ACE REN
22 interstitial emphysema 10.4 ACE MTHFR NOTCH3
23 cryptosporidiosis 10.4 F2 MTHFR SELP
24 dysgammaglobulinemia 10.4 F2 MTHFR SELP
25 secretory diarrhea myopathy and deafness 10.4 ACE CRP PLAT
26 myh7-related myosin storage myopathy 10.4 CBS MTHFR MTR
27 encephalitozoonosis 10.4 APOE APP CBS
28 lynch syndrome 10.4 F2 MTHFR PLAT
29 ductal carcinoma in situ 10.4 F2 MTHFR PLAT
30 cerebral atherosclerosis 10.4
31 asphyxia neonatorum 10.4 ACE APOE PON1
32 myosclerosis, congenital 10.4 CBS MTHFR MTR
33 villous adenoma 10.4 ACE CRP F2 MTHFR
34 myopia 10.4 ACE F2 REN
35 homocystinuria due to mthfr deficiency 10.4 MTHFR MTR
36 zap-70 deficiency 10.4 APOB APOE
37 alcoholic gastritis 10.4 F2 MTHFR PLAT
38 capillary hemangioma 10.4 F2 MTHFR REN
39 ischemic optic neuropathy 10.4 ACE CRP F2 SELP
40 familial periodic paralysis 10.4 ACE CRP F2
41 pregnancy loss, recurrent 1 10.4 F2 MTHFR PLAT
42 autosomal dominant sideroblastic anemia 10.4 CBS MTHFR MTR
43 mental retardation, autosomal recessive 33 10.4 APOB CRP MTHFR
44 schizotypal personality disorder 10.4 ACE CRP REN
45 familial progressive hyperpigmentation 10.4 ACE F2
46 ocular hyperemia 10.4 F2 MTHFR SELP
47 leukocyte disease 10.3 CRP F2 MTHFR PLAT
48 deafness, autosomal recessive 79 10.3 ACE CRP REN
49 xerophthalmia 10.3 CRP F2 PLAT SELP
50 sertoli-leydig cell tumor 10.3 F2 MTHFR PLAT SELP

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety Disorder
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Cerebral Atherosclerosis
Cerebral Degeneration Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypertensive Encephalopathy Hypothyroidism
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Ischemic Heart Disease Labyrinthitis
Left Ventricular Outflow Tract Obstruction Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


headache, transient ischemic attacks, stereotypic symptoms, angina pectoris, back pain, chest pain, edema, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 SELP APOA1 APOB APOE
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 AGTR1 APOA1 APOB APOE APP COL4A1
2 cardiovascular system MP:0005385 10.41 PON1 REN SELP ACE ADM AGTR1
3 behavior/neurological MP:0005386 10.36 AGTR1 APOE APP COL4A1 CX3CR1 F2
4 growth/size/body region MP:0005378 10.36 ACE ACHE AGTR1 APOB APOE APP
5 hematopoietic system MP:0005397 10.31 ACE ACHE ADM AGTR1 APOE APP
6 mortality/aging MP:0010768 10.31 ACE ACHE ADM AGTR1 APOB APOE
7 immune system MP:0005387 10.27 AGTR1 APOB APOE APP CRP CX3CR1
8 cellular MP:0005384 10.26 ADM APOA1 APOB APOE APP COL4A1
9 nervous system MP:0003631 10.13 ACHE AGTR1 APOB APOE APP COL4A1
10 integument MP:0010771 10.09 ADM APOA1 APOE APP CX3CR1 F2
11 muscle MP:0005369 10.07 ACHE ADM APOB APOE APP COL4A1
12 reproductive system MP:0005389 9.97 ACE ACHE ADM APOB APOE APP
13 renal/urinary system MP:0005367 9.91 CX3CR1 NOTCH3 REN SELP ACE ADM
14 respiratory system MP:0005388 9.56 PLAT SELP APOE COL4A1 F2 NOTCH3
15 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 886)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
2
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
5
Mannitol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 69-65-8 453 6251
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1 10238-21-8 3488
8
Probucol Approved Phase 4 23288-49-5 4912
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
11
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
12
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
13
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
15
Nicardipine Approved Phase 4,Phase 3,Phase 2,Phase 1 55985-32-5 4474
16
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 7439-89-6 23925
17
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
18
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
19
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
20
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
21
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
22
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Early Phase 1 103-90-2 1983
23
Ibuprofen Approved Phase 4 15687-27-1 3672
24
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
25
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
26
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
27
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
28
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
29
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
30
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
31
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
32
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
33
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
34
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2 55-63-0 4510
35
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 6691 54678486
36
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2 120014-06-4 3152
37
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
38
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
39 Piracetam Approved Phase 4,Phase 3,Phase 1 7491-74-9
40
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
41
Cilostazol Approved Phase 4,Phase 3,Phase 2 73963-72-1 2754
42
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 75614-87-8, 51-45-6 774
43
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
44
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
45
Nimodipine Approved Phase 4,Phase 3,Phase 1,Phase 2 66085-59-4 4497
46
Rimonabant Approved, Investigational Phase 4,Phase 3 168273-06-1, 158681-13-1 104850
47
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
48
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
49
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
50
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158

Interventional clinical trials:

(show top 50) (show all 4339)
id Name Status NCT ID Phase
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4
2 Nimodipine for Treating Acute Massive Cerebral Infarction Unknown status NCT02248233 Phase 4
3 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4
4 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
5 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4
6 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
7 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4
8 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
9 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4
10 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
11 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
12 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
13 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4
14 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
15 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
16 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4
17 The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients Unknown status NCT02361307 Phase 4
18 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
19 Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke Unknown status NCT02176395 Phase 4
20 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4
21 Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation Unknown status NCT00853866 Phase 4
22 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
23 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4
24 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4
25 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4
26 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4
27 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4
28 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4
29 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4
30 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4
31 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4
32 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4
33 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4
34 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4
35 Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis Unknown status NCT00772278 Phase 4
36 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4
37 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4
38 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
39 The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Unknown status NCT01042574 Phase 4
40 IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status NCT00325793 Phase 4
41 Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage Unknown status NCT01530880 Phase 4
42 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4
43 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4
44 HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study Unknown status NCT01516658 Phase 4
45 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4
46 Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage Unknown status NCT00699465 Phase 4
47 The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels Unknown status NCT01926834 Phase 4
48 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4
49 Normoglycemia and Neurological Outcome Unknown status NCT01137773 Phase 4
50 Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy Unknown status NCT00505505 Phase 4

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

39
Brain, Heart, Endothelial, Testes, Neutrophil, Thyroid, Pituitary

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 790)
id Title Authors Year
1
Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. ( 27980126 )
2017
2
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( 28072691 )
2017
3
Depression and Cerebrovascular Disease: What is to be Done? ( 28011139 )
2017
4
Which antihypertensive drug should be used in patients with cerebrovascular disease to prevent a new stroke? ( 28069253 )
2017
5
Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. ( 27909151 )
2017
6
CPAP did not reduce cardiovascular events in patients with coronary or cerebrovascular disease and moderate to severe obstructive sleep apnoea. ( 28069600 )
2017
7
Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. ( 28074678 )
2017
8
Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. ( 28070601 )
2017
9
Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. ( 27887801 )
2017
10
Robust segmentation and intelligent decision system for cerebrovascular disease. ( 27056410 )
2016
11
The Role of Cerebrovascular Disease inA Amyloid Deposition. ( 27567803 )
2016
12
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. ( 27489191 )
2016
13
Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. ( 27806707 )
2016
14
Validation of the Total Cerebrovascular Disease Burden Scale in a Community Sample. ( 27079726 )
2016
15
Availability of endovascular therapies for cerebrovascular disease at primary stroke centers. ( 27895242 )
2016
16
Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases. ( 27173177 )
2016
17
Cerebrovascular disease in children with HIV-1 infection. ( 26890389 )
2016
18
Is outdoor work associated with elevated rates of cerebrovascular disease mortality? A cohort study based on iron-ore mining. ( 27570536 )
2016
19
Cortical cerebral microinfarcts on 3T MRI: A novel marker of cerebrovascular disease. ( 27590296 )
2016
20
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. ( 27902730 )
2016
21
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. ( 27465265 )
2016
22
Genetic susceptibility to cerebrovascular disease. ( 26959706 )
2016
23
Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. ( 27084910 )
2016
24
The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer's Disease. ( 27662301 )
2016
25
Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. ( 27935239 )
2016
26
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( 26809135 )
2016
27
Imaging of cerebrovascular disease: a practical guide. ( 27852168 )
2016
28
Cerebrovascular Disease in Rheumatic Diseases: A Systematic Review and Meta-Analysis. ( 26917565 )
2016
29
Retinal vein occlusion and risk of cerebrovascular disease and myocardial infarction: A meta-analysis of cohort studies. ( 26922716 )
2016
30
Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. ( 27006480 )
2016
31
CerefolinNAC Therapy ofA Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer's Disease and Cerebrovascular Disease. ( 27567825 )
2016
32
Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. ( 26992016 )
2016
33
The relationship between the dietary inflammatory index and risk of total cardiovascular disease, ischemic heart disease and cerebrovascular disease: Findings from an Australian population-based prospective cohort study of women. ( 27498398 )
2016
34
Influence of cognitive function on cerebrovascular disease among the elderly. ( 27145203 )
2016
35
Frailty and sarcopenia in subjects with Alzheimer's disease with or without cerebrovascular disease. ( 27870509 )
2016
36
Novel imaging approaches to cerebrovascular disease. ( 27094991 )
2016
37
Cerebrovascular disease. ( 27637962 )
2016
38
Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan. ( 27495077 )
2016
39
Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease. ( 27559107 )
2016
40
Bacterial Endocarditis and Cerebrovascular Disease. ( 27815693 )
2016
41
Risk of premature cerebrovascular disease in patients with ankylosing spondylitis. ( 27182728 )
2016
42
Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. ( 27553104 )
2016
43
Impact of drinking and smoking habits on cerebrovascular disease risk among male employees. ( 27488512 )
2016
44
Calcium supplementation and risk of dementia in women with cerebrovascular disease. ( 27534711 )
2016
45
Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. ( 26983404 )
2016
46
Investigation of cerebral iron deposition in aged patients with ischemic cerebrovascular disease using susceptibility-weighted imaging. ( 27574434 )
2016
47
Role of transcranial Doppler in cerebrovascular disease. ( 27625245 )
2016
48
Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. ( 27082563 )
2016
49
Cerebrovascular disease: Lobar cerebral microbleeds signal early cognitive impairment. ( 27857119 )
2016
50
Aortic Complex Plaque Predicts the Risk of Cryptogenic Ischemic Cerebrovascular Disease Recurrence. ( 27114844 )
2016

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.61 APOA1 APOB APOE CBS CRP F2
3
Show member pathways
11.57 APOA1 APOB APOE COL4A1
4
Show member pathways
11.56 ACE AGTR1 REN
5
Show member pathways